Silence Therapeutics OTCPK:SLNC.F Stock Report

Silence Therapeutics plc, Annual General Meeting, Jun 14, 2022

Silence Therapeutics plc, Annual General Meeting, Jun 14, 2022, at 09:00 Eastern Daylight. Location: The Westin Jersey City Newport 479 Washington Blvd Jersey City New Jersey United States Agenda: To approve the power conferred by this resolution shall expire (unless previously revoked or varied by the Company in general meeting) at the conclusion of the next Annual General Meeting of the Company or the date 15 months from the date of passing of this resolution, whichever is the earlier, save that the Company may before such expiry, revocation or variation make an offer or agreement which would or might require equity securities to be allotted after such expiry, revocation or variation and the Directors may allot equity securities pursuant to such offer or agreement as if the power hereby conferred had not expired or been revoked or varied. This power is in substitution for any and all powers previously conferred on the Directors under Section 570 of the Companies Act, but without prejudice to any allotment of equity securities made or agreed to be made pursuant to such powers.

Silence Therapeutics Announces Detailed Results From SLN360 Phase 1 Study in High Lipoprotein(a) Presented in Late Breaker at the American College of Cardiology (ACC.22) Annual Meeting

Silence Therapeutics plc presented detailed results from its phase 1 APOLLO trial that showed SLN360, an investigational siRNA, reduced levels of lipoprotein(a) (“Lp(a)”), an important genetic risk factor for heart disease, by up to 98% in healthy adults with high Lp(a). Findings from the “APOLLO Trial: Magnitude and Duration of Effects of a Short-interfering RNA Targeting Lipoprotein(a): A Placebo-controlled Double-blind Dose-ranging Trial” were presented during a Late Breaking Science Session at the American College of Cardiology’s 71st Annual Scientific Session (ACC.22) and simultaneously published online in the Journal of the American Medical Association. The phase 1 APOLLO trial evaluated SLN360 in 32 adults at five medical centers in the U.S., UK and Netherlands. All participants had plasma concentrations at screening of Lp(a) =150 nmol/L with a median level of 224 nmol/L (75 nmol/L or less is considered normal). Individuals were randomly assigned to receive a single subcutaneous dose of SLN360 (30 mg, 100 mg, 300 mg or 600 mg) or placebo and were observed closely for the first 24 hours, then periodically assessed for 150 days. There were no serious safety concerns reported and the most common side effect was temporary redness at the injection site. Participants receiving 300 mg and 600 mg of SLN360 had up to 96% and 98% median reduction in Lp(a) levels, respectively, and median reductions of up to 71% and 81% from baseline persisted at 150 days. Those receiving a placebo saw no change in Lp(a) levels. The study follow-up period has been extended to 365 days to further assess the duration of action. Other efficacy measures included the effects of SLN360 on low-density lipoprotein cholesterol (LDL cholesterol) and apolipoprotein B (ApoB), both of which are associated with an increased risk of cardiovascular events. The highest doses of SLN360 reduced LDL cholesterol and ApoB by about 25%. Silence is evaluating SLN360 in the multiple-ascending dose portion of the APOLLO phase 1 study in patients with high Lp(a) that have a confirmed history of stable atherosclerotic cardiovascular disease (“ASCVD”). Silence plans to initiate the SLN360 phase 2 ASCVD study in the second half of 2022, pending regulatory discussions.

Silence Therapeutics plc to Report Q4, 2021 Results on Mar 17, 2022

Silence Therapeutics plc announced that they will report Q4, 2021 results on Mar 17, 2022

Silence Therapeutics plc Announces Executive Changes